Lecithin: cholesterol acyltransferase in Down's syndrome

Andras G. Lacko, James D. Hayes, Walter J. McConathy, Irene Lacko, R. Redheendran

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Based on earlier reports indicating that Down's syndrome may represent an atheroma-free human model, two groups of institutionalized subjects were compared with respect to various parameters of their plasma lipid transport system. One group of subjects was comprised of Down's syndrome subjects and the second, a group of mentally retarded individuals. Parameters measured included plasma cholesterol, triglyceride, HDL-cholesterol, apolipoprotein levels (A-I, B, C-III, and E), lecithin: cholesterol acyltransferase (LCAT) activity, body mass and blood pressure. Statistical analyses indicated no significant differences between the two groups except for the lower fractional rate of cholesterol esterification (% cholesterol esterified per hour, p = 0.0049) in the Down's syndrome subjects. Adjustment for the effects of body mass and age revealed no other significant differences between the two groups except for a lower molar rate of esterification (nmol cholesterol esterified · h-1, p < 0.0063) in the Down's syndrome subjects. Additional differences between the two groups were revealed by partial correlational analyses of LCAT activity with the measured parameters or ratios of these parameters which suggests that the composition and/or metabolism of lipoproteins may differ between these two groups. Whether the lower LCAT activity and the other differences reflected by the correlational analyses contribute to the decreased incidence of atherosclerotic lesions in Down's syndrome remains to be elucidated.

Original languageEnglish
Pages (from-to)133-141
Number of pages9
JournalClinica Chimica Acta
Volume132
Issue number2
DOIs
StatePublished - 15 Aug 1983

Fingerprint

Phosphatidylcholine-Sterol O-Acyltransferase
Down Syndrome
Cholesterol
Esterification
Plasmas
Apolipoproteins
Blood pressure
Metabolism
HDL Cholesterol
Lipoproteins
Mentally Disabled Persons
Apolipoprotein A-I
Atherosclerotic Plaques
Triglycerides
Lipids
Blood Pressure
Chemical analysis
Incidence

Cite this

Lacko, A. G., Hayes, J. D., McConathy, W. J., Lacko, I., & Redheendran, R. (1983). Lecithin: cholesterol acyltransferase in Down's syndrome. Clinica Chimica Acta, 132(2), 133-141. https://doi.org/10.1016/0009-8981(83)90241-3
Lacko, Andras G. ; Hayes, James D. ; McConathy, Walter J. ; Lacko, Irene ; Redheendran, R. / Lecithin : cholesterol acyltransferase in Down's syndrome. In: Clinica Chimica Acta. 1983 ; Vol. 132, No. 2. pp. 133-141.
@article{32739814d6a54617a37050876d8fb71e,
title = "Lecithin: cholesterol acyltransferase in Down's syndrome",
abstract = "Based on earlier reports indicating that Down's syndrome may represent an atheroma-free human model, two groups of institutionalized subjects were compared with respect to various parameters of their plasma lipid transport system. One group of subjects was comprised of Down's syndrome subjects and the second, a group of mentally retarded individuals. Parameters measured included plasma cholesterol, triglyceride, HDL-cholesterol, apolipoprotein levels (A-I, B, C-III, and E), lecithin: cholesterol acyltransferase (LCAT) activity, body mass and blood pressure. Statistical analyses indicated no significant differences between the two groups except for the lower fractional rate of cholesterol esterification ({\%} cholesterol esterified per hour, p = 0.0049) in the Down's syndrome subjects. Adjustment for the effects of body mass and age revealed no other significant differences between the two groups except for a lower molar rate of esterification (nmol cholesterol esterified · h-1, p < 0.0063) in the Down's syndrome subjects. Additional differences between the two groups were revealed by partial correlational analyses of LCAT activity with the measured parameters or ratios of these parameters which suggests that the composition and/or metabolism of lipoproteins may differ between these two groups. Whether the lower LCAT activity and the other differences reflected by the correlational analyses contribute to the decreased incidence of atherosclerotic lesions in Down's syndrome remains to be elucidated.",
author = "Lacko, {Andras G.} and Hayes, {James D.} and McConathy, {Walter J.} and Irene Lacko and R. Redheendran",
year = "1983",
month = "8",
day = "15",
doi = "10.1016/0009-8981(83)90241-3",
language = "English",
volume = "132",
pages = "133--141",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "2",

}

Lacko, AG, Hayes, JD, McConathy, WJ, Lacko, I & Redheendran, R 1983, 'Lecithin: cholesterol acyltransferase in Down's syndrome', Clinica Chimica Acta, vol. 132, no. 2, pp. 133-141. https://doi.org/10.1016/0009-8981(83)90241-3

Lecithin : cholesterol acyltransferase in Down's syndrome. / Lacko, Andras G.; Hayes, James D.; McConathy, Walter J.; Lacko, Irene; Redheendran, R.

In: Clinica Chimica Acta, Vol. 132, No. 2, 15.08.1983, p. 133-141.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lecithin

T2 - cholesterol acyltransferase in Down's syndrome

AU - Lacko, Andras G.

AU - Hayes, James D.

AU - McConathy, Walter J.

AU - Lacko, Irene

AU - Redheendran, R.

PY - 1983/8/15

Y1 - 1983/8/15

N2 - Based on earlier reports indicating that Down's syndrome may represent an atheroma-free human model, two groups of institutionalized subjects were compared with respect to various parameters of their plasma lipid transport system. One group of subjects was comprised of Down's syndrome subjects and the second, a group of mentally retarded individuals. Parameters measured included plasma cholesterol, triglyceride, HDL-cholesterol, apolipoprotein levels (A-I, B, C-III, and E), lecithin: cholesterol acyltransferase (LCAT) activity, body mass and blood pressure. Statistical analyses indicated no significant differences between the two groups except for the lower fractional rate of cholesterol esterification (% cholesterol esterified per hour, p = 0.0049) in the Down's syndrome subjects. Adjustment for the effects of body mass and age revealed no other significant differences between the two groups except for a lower molar rate of esterification (nmol cholesterol esterified · h-1, p < 0.0063) in the Down's syndrome subjects. Additional differences between the two groups were revealed by partial correlational analyses of LCAT activity with the measured parameters or ratios of these parameters which suggests that the composition and/or metabolism of lipoproteins may differ between these two groups. Whether the lower LCAT activity and the other differences reflected by the correlational analyses contribute to the decreased incidence of atherosclerotic lesions in Down's syndrome remains to be elucidated.

AB - Based on earlier reports indicating that Down's syndrome may represent an atheroma-free human model, two groups of institutionalized subjects were compared with respect to various parameters of their plasma lipid transport system. One group of subjects was comprised of Down's syndrome subjects and the second, a group of mentally retarded individuals. Parameters measured included plasma cholesterol, triglyceride, HDL-cholesterol, apolipoprotein levels (A-I, B, C-III, and E), lecithin: cholesterol acyltransferase (LCAT) activity, body mass and blood pressure. Statistical analyses indicated no significant differences between the two groups except for the lower fractional rate of cholesterol esterification (% cholesterol esterified per hour, p = 0.0049) in the Down's syndrome subjects. Adjustment for the effects of body mass and age revealed no other significant differences between the two groups except for a lower molar rate of esterification (nmol cholesterol esterified · h-1, p < 0.0063) in the Down's syndrome subjects. Additional differences between the two groups were revealed by partial correlational analyses of LCAT activity with the measured parameters or ratios of these parameters which suggests that the composition and/or metabolism of lipoproteins may differ between these two groups. Whether the lower LCAT activity and the other differences reflected by the correlational analyses contribute to the decreased incidence of atherosclerotic lesions in Down's syndrome remains to be elucidated.

UR - http://www.scopus.com/inward/record.url?scp=0020628946&partnerID=8YFLogxK

U2 - 10.1016/0009-8981(83)90241-3

DO - 10.1016/0009-8981(83)90241-3

M3 - Article

C2 - 6225568

AN - SCOPUS:0020628946

VL - 132

SP - 133

EP - 141

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 2

ER -